Change in the use of proceeds from stock acquisition rights to be issued in a third-party allotment. Allocate 280 million yen to the grid-scale battery business, while reducing the allocation to the regenerative medicine-related business from 686 million yen to 405 million yen. The timing for working capital and expenditures for the regenerative medicine-related business is extended to 2025\/1\u20132027\/6; part of the expenditure timing is extended through June 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2721","jir_company_name":"J-Holdings Corp.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/2721-20260930-02.pdf","jir_short_summary":"Change in the use of proceeds from stock acquisition rights to be issued in a third-party allotment. Allocate 280 million yen to the grid-scale battery business, while reducing the allocation to the regenerative medicine-related business from 686 million yen to 405 million yen. The timing for working capital and expenditures for the regenerative medicine-related business is extended to 2025\/1\u20132027\/6; part of the expenditure timing is extended through June 2027.","jir_summary":"### Summary of the News\nThis document reports a resolution to change the use of proceeds disclosed in the notice dated January 15, 2025 regarding the solicitation of the 8th series of stock acquisition rights, based on future business progress. Specifically, an additional 280 million yen will be allocated to the grid-scale battery business, while the allocation to the regenerative medicine-related business will be reduced from 686 million yen to 405 million yen. The timing of expenditures for working capital and the regenerative medicine-related business will be extended through June 2027, and funds for the grid-scale battery allocation are scheduled for September 2026.\n\n### Future Impact and Outlook\nThe change in use of proceeds is expected to have a minor impact on consolidated results for the fiscal year ending December 2026, and additional disclosures will be made depending on progress. The company intends to balance the new business area (grid-scale batteries) with the regenerative medicine-related business and flexibly revise fund allocation according to funding needs.","jir_financial_highlights":"Working capital: 318 million yen (After change: January 2025 \u2013 June 2027)\nRegenerative medicine-related business: 405 million yen (After change: expenditure period extended to January 2025 \u2013 June 2027)\nGrid-scale battery business: 280 million yen (New allocation)","jir_category":"","jir_hashtags":"#J-Holdings, #ChangeInCapitalPolicy, #StockAcquisitionRights, #GridScaleBattery","jir_key_figures":"Working capital: 318 million yen (after change, 2025\/1\u20132027\/6)\nRegenerative medicine-related business: 405 million yen (after change, 2025\/1\u20132027\/6)\nGrid-scale battery business: 280 million yen (planned allocation, 2026\/9)","jir_meta_title":"J-Holdings Corp. Changes Use of Proceeds for Third-Party Allotment | Additional Investment in Grid-Scale Batteries \u2013 September 2026","jir_meta_description":"J-Holdings Corp. has changed the use of proceeds from a third-party allotment. 280 million yen will be allocated to the grid-scale battery business, the allocation to the regenerative medicine-related business is reduced, and the timing for working capital and expenditures is extended through June 2027. Analysis of future impact and outlook.","jir_og_title":"J-Holdings Corp. Changes Use of Proceeds for Third-Party Allotment | New Investment Policy","jir_og_description":"J-Holdings Corp. announced a change in the use of proceeds. Additional investment in grid-scale batteries, reduced allocation to regenerative medicine-related business, and extended timing for working capital expenditures. Expected impact on results is minor.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":61243,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-125324","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n